Biogen Inc. $BIIB Shares Sold by Sumitomo Mitsui Trust Group Inc.

Posted by Stanley Muller on Nov 4th, 2026

Sumitomo Mitsui Trust Group Inc. trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 2.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 336,692 shares of the biotechnology company’s stock after selling 9,925 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.23% of Biogen worth $76,052,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Biogen during the second quarter valued at $3,453,878,000. Primecap Management Co. CA acquired a new stake in Biogen in the second quarter worth $3,274,304,000. Wellington Management Group LLP lifted its stake in Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after buying an additional 155,828 shares during the last quarter. Amundi boosted its holdings in shares of Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after acquiring an additional 726,004 shares during the period. Finally, Legal & General Group Plc acquired a new position in shares of Biogen during the second quarter valued at $322,640,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Down 0.0%

Shares of BIIB stock opened at $248.93 on Wednesday. Biogen Inc. has a 1 year low of $148.51 and a 1 year high of $258.78. The firm has a market capitalization of $36.80 billion, a PE ratio of 106.38, a price-to-earnings-growth ratio of 2.82 and a beta of 0.10. The stock has a fifty day moving average of $228.34 and a two-hundred day moving average of $201.80. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.63 billion. During the same period last year, the company earned $4.81 earnings per share. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. As a group, research analysts expect that Biogen Inc. will post 12.47 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. TD Cowen upped their price target on shares of Biogen from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. HC Wainwright boosted their target price on shares of Biogen from $251.00 to $270.00 and gave the company a “buy” rating in a research note on Monday. BMO Capital Markets restated a “market perform” rating and issued a $220.00 target price on shares of Biogen in a research report on Monday, October 12th. Robert W. Baird raised their price target on shares of Biogen from $250.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Finally, Wedbush lifted their price target on Biogen from $212.00 to $225.00 and gave the company a “neutral” rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and an average price target of $252.34.

Get Our Latest Stock Report on Biogen

About Biogen

(Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.